HCC: Key topics discussed at ASCO GI & EASL 2022

December 06, 2023 00:13:11
HCC: Key topics discussed at ASCO GI & EASL 2022
COR2ED - Oncology Medical Conversation
HCC: Key topics discussed at ASCO GI & EASL 2022

Dec 06 2023 | 00:13:11

/

Show Notes

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.

Other Episodes

Episode

February 23, 2024 00:32:21
Episode Cover

Ovarian cancer: Pre-analytical phase challenges and biomarker testing

What are the common pre-analytical phase challenges in ovarian cancer, and how can we overcome them? Why is it important to identify genetic alterations?  ...

Listen

Episode

May 07, 2024 00:27:54
Episode Cover

Interpreting real-world evidence in later-line mCRC

What are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be used to...

Listen

Episode

January 07, 2025 00:20:19
Episode Cover

Intermediate HCC – treatment options and strategies

In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr...

Listen